A Research Guide for
Schizophrenia

Before settling on a schizophrenia diagnosis, clinicians consider substance-induced psychosis (cannabis, stimulants, and others), mood disorders with psychotic features (such as bipolar disorder or severe depression), and medical causes including thyroid disease, certain infections, and a treatable autoimmune condition called anti-NMDA-receptor encephalitis. Asking “have all of these been considered?” is reasonable and welcomed by good clinicians.

The period of time between when psychotic symptoms begin and when effective treatment starts is called the duration of untreated psychosis (DUP). Shorter DUP is linked to better recovery. This is the single strongest reason not to “wait and see.”

For a first episode, the best-supported approach is Coordinated Specialty Care (CSC) — a team-based program that combines a low dose of antipsychotic medication, therapy, family education, help with school or work, and case management. The U.S. RAISE/NAVIGATE study showed CSC meaningfully improves outcomes when started within roughly the first two years of psychosis. CSC programs are available in most U.S. states; use the SAMHSA Early Serious Mental Illness Treatment Locator to find the nearest program.

One of the most painful and confusing parts of schizophrenia is that many people genuinely do not believe they are ill. This is anosognosia — a neurological symptom of the illness itself, caused by changes in the brain regions that allow self-awareness. It is the same phenomenon seen after some strokes, where a person cannot perceive a real impairment.

This is not denial, stubbornness, or a character flaw, and arguing about “the facts” usually does not work. Approaches that do help include staying connected, focusing on shared goals (sleep, calm, getting back to work) rather than on whether the person “has schizophrenia,” and using a supportive communication style. Clinicians and families often use a method called LEAP (Listen, Empathize, Agree, Partner). Understanding anosognosia is the key to keeping someone engaged in treatment.

• What other causes of these symptoms have been ruled out, and what tests were done?
• Is this being treated as a first episode of psychosis? Are we within the early-intervention window?
• How will the diagnosis be confirmed or revisited over time?
• If my family member does not believe they are ill, how should we handle conversations about treatment?
• What should we do, step by step, if symptoms suddenly get worse?

These include aripiprazole, risperidone, paliperidone, quetiapine, olanzapine, ziprasidone, lurasidone, cariprazine, brexpiprazole, and lumateperone. They all work mainly by adjusting dopamine signaling. They differ most in their side-effect profiles — especially weight gain and metabolic risk. For example, olanzapine and quetiapine tend to cause more weight gain; aripiprazole, lurasidone, lumateperone, and ziprasidone tend to cause less. Cariprazine has some evidence for negative symptoms. The “best” choice balances effectiveness for that person against the side effects they can live with.

Older medications such as haloperidol, fluphenazine, and chlorpromazine are effective against positive symptoms but carry a higher risk of movement-related side effects (stiffness, restlessness, and tardive dyskinesia). They are still used — particularly in acute hospital settings and as long-acting injectable formulations — but they are usually not the first choice for ongoing treatment.

The evidence so far. In three clinical trials (EMERGENT-1, -2, and -3), Cobenfy reduced symptoms of schizophrenia significantly more than placebo over five weeks. Longer-term and switching studies (such as the year-long EMERGENT-5) have followed.

The big advantage. In clinical trials, no weight gain, no metabolic syndrome, and no movement disorders — the side effects that lead many people to stop taking older medications.

The side effects it does have. Mostly stomach-related — nausea, constipation, vomiting, indigestion, dry mouth — because of the cholinergic mechanism. It can also raise heart rate and blood pressure modestly.

Dosing. Typically started at 50 mg xanomeline / 20 mg trospium twice daily, increasing over about a week to the target dose of 125/30 mg twice daily.

Who should not take it. People with untreated narrow-angle glaucoma, urinary retention, or severe gastrointestinal motility problems. It is contraindicated in moderate-to-severe liver impairment. Post-marketing safety monitoring has identified signals for urinary retention and excess salivation — tell your doctor about all medical conditions before starting.

What it has not shown. It has not been compared head-to-head against existing antipsychotics, so no one can yet say it is “stronger.” A 2025 trial (ARISE) testing Cobenfy added on top of another antipsychotic did not meet its main goal — so it is currently approved on its own, not as an add-on. Long-term data are still accumulating.

Real-world barriers. Cost and insurance coverage can be obstacles, and some psychiatrists are still becoming familiar with this new mechanism. It is reasonable to ask directly whether it is an option and whether your insurance covers it.

An LAI delivers steady medication from a single injection, removing the daily pressure of remembering pills. Paliperidone palmitate comes as a monthly (Invega Sustenna), 3-monthly (Invega Trinza), and 6-monthly (Invega Hafyera) injection. Other options include aripiprazole formulations (Abilify Maintena monthly, Abilify Asimtufii every two months, Aristada monthly/every six weeks/every two months), risperidone formulations (Risperdal Consta, Uzedy, Rykindo), and the older haloperidol and fluphenazine decanoate. Choosing an LAI is a shared decision — many people find that not thinking about medication every day is itself a relief.

Why it is special. For schizophrenia that has not responded to other medications, clozapine often works when nothing else has. It also reduces suicidal behavior — the only antipsychotic proven to do so.

Monitoring. Clozapine can rarely lower a type of infection-fighting white blood cell, so regular blood tests (absolute neutrophil count, or ANC) are still recommended — frequently at first, then less often. As of 2025, this monitoring is no longer enforced through a federal restricted-distribution program, which removes a major access barrier, but the blood tests themselves remain part of safe care.

Other side effects to know. Drooling (especially at night), sedation, constipation (which must be taken seriously), weight gain and metabolic effects, and — rarely — inflammation of the heart muscle (myocarditis), usually in the first weeks. These are manageable with good monitoring, and the team will explain what to watch for.

If you smoke and take clozapine. Smoking cigarettes speeds up the breakdown of clozapine in the body (through an enzyme called CYP1A2). If you stop or reduce smoking — even for a few days — clozapine levels can rise significantly, causing increased side effects. Always tell your treatment team immediately if you change your smoking habits so they can adjust the dose.

A note on benign ethnic neutropenia. Some people, especially those of African descent, naturally have lower white blood cell counts. This is called benign ethnic neutropenia and is a normal variation, not a sign of danger. Historically, this has been a barrier to starting clozapine because lab results appeared falsely abnormal. If clozapine is being withheld because of low blood counts, ask whether benign ethnic neutropenia has been considered.

If a clinician has not raised clozapine after two medications have not worked, it is very reasonable to ask, “Are we at the point of considering clozapine?”

Tardive dyskinesia (TD) is a movement side effect — involuntary movements of the face, mouth, or limbs — that can develop after long-term use of dopamine-blocking antipsychotics. It was once considered essentially permanent. Two medications, valbenazine (Ingrezza) and deutetrabenazine (Austedo), are now FDA-approved to treat it and can substantially reduce the movements. Everyone on antipsychotics should be screened regularly (clinicians use a brief exam called the AIMS), because catching TD early leads to better outcomes.

Some common herbal supplements can interfere with antipsychotic medications in potentially dangerous ways. St. John’s Wort can dramatically reduce levels of quetiapine, aripiprazole, clozapine, and other antipsychotics, risking relapse. CBD and cannabis products can theoretically increase antipsychotic levels; cannabis also worsens psychosis independently. Kava has caused severe sedation (including reported cases of coma when combined with sedating medications) and carries hepatotoxicity risk. Ginkgo biloba may increase clozapine levels. Always tell your treatment team about any supplements, herbal products, or cannabis use — this is not about judgment but about keeping medications safe and effective.

Cognitive behavioral therapy for psychosis (CBTp) helps a person cope with and reduce the distress of voices and unusual beliefs. Cognitive remediation therapy (CRT) targets memory, attention, and problem-solving. Family psychoeducation gives families the skills and knowledge that reduce relapse by up to 50% in well-designed studies. Social skills training (SST) helps build practical interpersonal and daily-living skills and has strong evidence from the PORT recommendations. Supported employment — specifically the Individual Placement and Support (IPS) model — helps people find and keep real jobs. Assertive Community Treatment (ACT) provides intensive, team-based support for people with the highest needs. Ask which of these are available locally.

• Which medication are you recommending, and why this one for us specifically?
• What side effects should we expect, and which ones mean we should call you right away?
• How will weight, blood sugar, and cholesterol be monitored while on this medication?
• Is Cobenfy (KarXT) an option for us? Would my insurance cover it?
• Should we consider a long-acting injectable now, rather than later? What are the pros and cons?
• If this medication does not work well enough, what is the next step — and at what point would we consider clozapine?
• Am I (or my family member) being screened for tardive dyskinesia? How often?
• What therapy, cognitive remediation, or supported-employment services can you refer us to?
• Is there an early-psychosis / coordinated specialty care team we can join?
• If pregnancy is a possibility, what are the risks and benefits of continuing medication? Which medications are safest during pregnancy and breastfeeding?
• What is the plan if symptoms return — who do we call, and what happens?

Consistency is one of the strongest predictors of staying well. Helpful strategies include pill organizers, phone reminders, linking doses to daily routines, and — for many people — choosing a long-acting injectable so daily pills are not a concern at all. If side effects are the reason for skipping doses, tell the team; the answer is almost always to adjust treatment, not to stop. Stopping antipsychotics suddenly can trigger a rapid relapse.

People with schizophrenia, on average, live 15–20 years less than the general population — and the leading cause is cardiovascular disease, not the psychiatric illness itself. Some antipsychotics contribute through weight gain and changes in blood sugar and cholesterol. This is manageable: regular monitoring, attention to diet and physical activity, not smoking (or getting support to quit), and sometimes adding a medication such as metformin. Treating physical health is as important as treating symptoms.

Cannabis, stimulants, and alcohol can worsen psychosis, trigger relapse, and interfere with medication. Cannabis in particular is linked with worse outcomes in schizophrenia. This is not about blame — many people use substances to cope with distressing symptoms. The most effective approach treats mental health and substance use together (“integrated dual-disorder treatment”). It is worth telling the team honestly about any substance use so they can help.

Relapse rarely happens without warning. Common early signs include changes in sleep (especially sleeping much less), social withdrawal, increasing suspiciousness, trouble concentrating, unusual preoccupations, and speech that becomes harder to follow. Many people and families create a written “relapse signature” — the specific early signs unique to that person — together with a plan for what to do if they appear. Acting early on warning signs can prevent a full crisis.

You often see changes before anyone else does. Watch for disrupted sleep, pulling away from people, irritability or rising suspiciousness, neglecting hygiene, and speech that becomes disorganized or hard to follow. Keep a simple written list of this person’s particular early signs, and agree in advance — while the person is well — on what steps to take if those signs appear. Early action prevents crises.

Try to support rather than police. Gentle routines, shared calendars, and a non-judgmental tone work better than confrontation. If staying on daily pills is a recurring struggle, talk with the team about a long-acting injectable — it can remove the daily friction entirely. Keep a record of injection dates and the next appointment so a dose is never missed.

If your family member insists nothing is wrong, remember this is most likely anosognosia — a brain-based inability to perceive the illness — not denial or defiance. Arguing about the diagnosis usually backfires. Instead, stay connected, avoid making your relationship conditional on them “admitting” they are ill, and focus conversations on goals you both want (better sleep, less stress, getting back to work or school). The LEAP approach — Listen, Empathize, Agree, Partner — was developed for exactly this and is worth learning.

When someone is frightened or agitated: keep your voice calm and low, give them physical space, reduce noise and stimulation, avoid sudden movements, and do not argue about whether their fears are “real” — acknowledge the feeling instead (“that sounds really frightening”). Keep an exit path clear for both of you. If you ever feel unsafe, or if there are threats of harm, prioritize safety and call 988 or 911. Some areas have mental-health crisis teams that can respond instead of, or alongside, police — ask your local crisis line in advance.

If someone is at serious risk because of their illness and will not accept help, an emergency psychiatric evaluation (sometimes called an involuntary hold or civil commitment) may become necessary. Criteria and processes vary by state; in Utah they are set out in state mental-health law. Some families also pursue guardianship or conservatorship for ongoing decision-making. These are difficult steps — an attorney experienced in mental-health law, and your local NAMI affiliate, can help you understand the options. Where possible, discussing an advance psychiatric directive while the person is well lets them state their own treatment preferences ahead of time.

Caregiver burnout is real and common. Protect your own sleep, health, and relationships, and accept that you cannot pour from an empty cup. Look into respite options, peer support, and family programs (NAMI’s Family-to-Family course is free and excellent). Many caregivers also carry a quiet grief for the person they knew before the illness — that grief is valid, and it deserves support of its own, including counseling. Connecting with other families who understand can be the single most sustaining thing you do.

Keep a written crisis plan: warning signs, current medications, the treatment team’s contact information, the local crisis line, and the nearest psychiatric emergency service. On the practical side, families often need to navigate insurance, disability benefits (such as SSI/SSDI), housing programs, and long-term-care planning. Community mental health centers and NAMI can connect you with case managers and benefits counselors who do this work every day — you do not have to figure it out alone.

• What are the specific early warning signs we should watch for in our situation?
• Can we make a written relapse-prevention and crisis plan together?
• How often will physical health (weight, blood sugar, cholesterol, blood pressure) be checked?
• What support is available for quitting smoking or reducing substance use?
• What family education or caregiver support programs do you recommend?
• How can we set up an advance psychiatric directive?

Employment is one of the strongest contributors to recovery and self-worth. The Individual Placement and Support (IPS) model — supported employment — helps people find and keep competitive jobs while still in treatment, and it has a strong evidence base. Supported education programs do the same for school. Ask your team for a referral; do not wait until symptoms are “perfect.”

Stable housing is a foundation for everything else — supported housing programs exist and case managers can help access them. Rebuilding relationships takes time and patience on all sides. Peer support — connecting with others who have lived experience — and clubhouse programs (community centers built around shared work and belonging) help many people rebuild a social world and a sense of purpose.

Regular sleep, physical activity, a reasonable diet, avoiding cannabis and stimulants, managing stress, and staying socially connected all measurably support stability. None of these replace medication and treatment — they work alongside them. Small, sustainable routines beat ambitious plans that do not last.

The field is advancing faster than it has in decades. A digital therapeutic for negative symptoms (CT-155) may become the first FDA-cleared app for schizophrenia. New muscarinic medicines beyond Cobenfy are entering Phase 3 trials, though some promising approaches (including emraclidine and ulotaront) did not succeed in clinical trials. For treatment-resistant schizophrenia, a glutamate-modulating drug (evenamide) is in late-stage testing. Smartphone tools that detect early relapse warning signs from daily phone use patterns are being validated in multiple studies. None of this replaces what works today — but it means there is real reason for cautious optimism about what will be available in the coming years.

Research consistently shows that Black Americans are approximately three times more likely to receive a schizophrenia diagnosis, and are less likely to receive clozapine or other optimal treatments for equivalent severity. These disparities reflect systemic bias in healthcare, not differences in the illness itself. If you or a family member feel that a diagnosis or treatment plan does not fit, seeking a second opinion is appropriate and welcomed by good clinicians. You have the right to culturally sensitive care, to a thorough evaluation, and to ask questions about the reasoning behind any diagnosis.

• What does recovery realistically look like for us, and what goals should we set?
• Can you refer us to supported employment (IPS) or supported education?
• What housing supports or case management are available?
• Are there peer support specialists or clubhouse programs we can connect with?
• How do we balance long-term medication with the goal of living fully?

• 988 Suicide & Crisis Lifeline — call or text 988, any time, for any mental health crisis.
• NAMI (National Alliance on Mental Illness) — the NAMI HelpLine and free education programs for individuals and families, including Family-to-Family.
• SAMHSA National Helpline — 1-800-662-HELP (4357), free and confidential treatment referral and information, 24/7.
• Schizophrenia & Psychosis Action Alliance — advocacy, education, and support resources.
• SAMHSA Early Serious Mental Illness Treatment Locator — to find coordinated specialty care programs.

• Huntsman Mental Health Institute (HMHI), University of Utah (formerly the University Neuropsychiatric Institute / UNI, renamed in 2021) — comprehensive psychiatric services including a first-episode psychosis program, crisis stabilization and a walk-in crisis/receiving center, inpatient and outpatient care, intensive outpatient programs, and clinical research/trials. (UNI is the former name of this same institution, not a separate facility.)
• Intermountain Health Behavioral Health Services — outpatient psychiatry, crisis services, and peer support across the Wasatch Front.
• NAMI Utah — Family-to-Family education, support groups for individuals and families, and advocacy.
• Wasatch Behavioral Health — community mental health center for Utah County; assertive community treatment (ACT), supported employment, case management.
• Valley Behavioral Health — Salt Lake County community mental health; housing support, vocational services, integrated care.
• Utah Division of Substance Abuse and Mental Health (DSAMH) — state-funded services, the 988 crisis line, and PATH homeless outreach.
• Clubhouse programs in Utah — Fountain House–model psychosocial rehabilitation, peer support, and transitional/supported employment.

• Emraclidine (CVL-231) — FAILED A muscarinic M4-selective agonist developed by Cerevel Therapeutics (later acquired by AbbVie). After promising Phase 1b results, emraclidine failed to separate from placebo in two Phase 2 trials (EMPOWER-1 and EMPOWER-2) reported in 2024. Development was discontinued. This underscored that the muscarinic approach taken by Cobenfy (which activates both M1 and M4 receptors) may require dual-receptor engagement.
• Ulotaront (SEP-363856) — FAILED A TAAR1/5-HT1A agonist developed by Sunovion/Sumitomo Pharma as a non-dopaminergic antipsychotic. Despite encouraging Phase 2 results, ulotaront failed both pivotal Phase 3 trials (DIAMOND-1 and DIAMOND-2) in 2023, showing no significant benefit over placebo. Development for schizophrenia was halted.
• Bitopertin — FAILED A glycine reuptake inhibitor (GlyT1 inhibitor) developed by Roche to target negative symptoms by enhancing NMDA-receptor signaling through glutamate modulation. After multiple large Phase 3 trials (SearchLyte and FlashLyte programs) failed to show meaningful benefit for either negative or positive symptoms, Roche discontinued development in 2014.
• Iclepertin (BI 425809) — FAILED A glycine reuptake (GlyT1) inhibitor developed by Boehringer Ingelheim to treat cognitive impairment associated with schizophrenia. Its large Phase 3 CONNEX program (CONNEX-1/-2/-3; ~1,840 participants across 41 countries) failed to improve cognition or daily functioning; the negative results were reported in January 2025. This was a major setback for the glutamatergic approach to cognition, which remains the hardest symptom domain to treat.
• Roluperidone (MIN-101) — NOT APPROVED A sigma-2/5-HT2A agent developed by Minerva for negative symptoms. The FDA issued a Complete Response Letter in February 2024, citing insufficient evidence of effectiveness and requiring an additional confirmatory trial; it is not approved.
• Pomaglumetad methionil (LY2140023) — FAILED An mGlu2/3 receptor agonist developed by Eli Lilly as a glutamate-based antipsychotic. An initial Phase 2 trial showed promise, but subsequent larger trials failed to replicate the finding. Lilly terminated development in 2012. The compound represented one of the most rigorous tests of the glutamate hypothesis of schizophrenia, and its failure set back the field significantly.
• Insulin coma therapy — DE-ADOPTED Widely used from the 1930s through the 1960s, insulin coma therapy involved inducing daily hypoglycemic comas. A landmark 1957 controlled study showed it was no more effective than barbiturate-induced sleep, and it carried significant risks including brain damage and death. It was abandoned after the introduction of chlorpromazine.
• Prefrontal lobotomy — DE-ADOPTED Once performed on tens of thousands of patients with schizophrenia and other conditions (earning its developer a Nobel Prize in 1949), lobotomy caused permanent cognitive and personality changes, and was abandoned following the introduction of antipsychotic medications in the 1950s and accumulating evidence of devastating outcomes.
• Megavitamin/orthomolecular therapy — FAILED High-dose niacin (vitamin B3) and other vitamins were proposed as a treatment for schizophrenia by Abram Hoffer and Humphry Osmond in the 1960s. Multiple controlled trials and an American Psychiatric Association task force review (1973) found no benefit. The approach is not supported by evidence, but continues to circulate in alternative-health communities.

• Benzodiazepine monotherapy — DE-ADOPTED Benzodiazepines (such as lorazepam and diazepam) were once used alone to treat acute psychosis. Evidence does not support their use as a sole treatment for schizophrenia. They remain useful as short-term adjuncts for acute agitation or anxiety alongside antipsychotics, but monotherapy is ineffective for the core illness and carries risks of dependence.

When evaluating any treatment — whether new or established — the right question is always: “What does the published evidence show?” Ask your treatment team to explain the evidence behind any recommended approach.

• Positive symptoms — experiences that are “added” to a person’s reality and are not present in healthy individuals: hallucinations (most often hearing voices), delusions (fixed false beliefs), and disorganized thinking or speech. Called “positive” because they represent an excess of normal function, not because they are good. These tend to respond best to antipsychotic medication.
• Negative symptoms — things that are reduced or absent compared with healthy functioning: diminished emotional expression, lack of motivation (avolition), reduced speech (alogia), social withdrawal, and difficulty experiencing pleasure (anhedonia). Often the most disabling symptoms over the long term and less responsive to current medications.
• Cognitive symptoms — difficulties with attention, working memory, processing speed, and executive function (planning, organizing, flexible thinking). These strongly affect a person’s ability to work, study, and manage daily life. Cognitive remediation therapy is the main evidence-based approach.

• Antipsychotic — first-generation (typical) — older dopamine-blocking medications such as haloperidol, fluphenazine, and chlorpromazine. Effective against positive symptoms but carry a higher risk of movement-related side effects (EPS, tardive dyskinesia).
• Antipsychotic — second-generation (atypical) — newer medications including aripiprazole, risperidone, paliperidone, quetiapine, olanzapine, ziprasidone, lurasidone, cariprazine, brexpiprazole, and lumateperone. They adjust dopamine and serotonin signaling and generally carry lower risk of movement side effects but variable metabolic risk (weight gain, blood sugar, cholesterol).
• Clozapine — the only antipsychotic FDA-approved specifically for treatment-resistant schizophrenia and the only one proven to reduce suicide risk. Requires blood-count monitoring (ANC) because it can rarely lower infection-fighting white blood cells. As of 2025, the restrictive REMS program has been eliminated, improving access.
• LAI (long-acting injectable) — antipsychotic formulations delivered by injection every 1, 2, 3, or 6 months instead of daily pills. Examples include paliperidone palmitate (Invega Sustenna/Trinza/Hafyera), aripiprazole formulations (Abilify Maintena, Aristada), and risperidone formulations. Strongly reduces relapse risk by ensuring consistent medication levels.
• VMAT2 inhibitor — a class of medication (valbenazine/Ingrezza, deutetrabenazine/Austedo) that treats tardive dyskinesia by reducing dopamine release at nerve terminals. These are the first FDA-approved treatments for TD.

• Tardive dyskinesia (TD) — involuntary, repetitive movements (often of the face, mouth, tongue, or limbs) that can develop after prolonged use of dopamine-blocking antipsychotics. Once considered permanent, it is now treatable with VMAT2 inhibitors. Early detection through regular screening leads to better outcomes.
• AIMS (Abnormal Involuntary Movement Scale) — a brief clinical examination used to screen for tardive dyskinesia. Clinicians rate movements of the face, extremities, and trunk on a 0–4 scale. Everyone on antipsychotics should be screened regularly.
• EPS (extrapyramidal symptoms) — a group of movement side effects caused by dopamine blockade, including muscle stiffness (dystonia), restlessness (akathisia), tremor, and slowness of movement (bradykinesia). More common with first-generation antipsychotics.
• Akathisia — a deeply uncomfortable inner restlessness and inability to sit still, caused by some antipsychotics. Often described as feeling like you need to move constantly. It is a common reason people stop medication and should be reported to the treatment team immediately, as it is treatable.
• Metabolic syndrome — a cluster of conditions — increased waist circumference, elevated blood sugar, high triglycerides, low HDL cholesterol, and high blood pressure — that together raise the risk of heart disease and diabetes. Some antipsychotics (especially olanzapine and clozapine) increase this risk, making regular metabolic monitoring essential.
• Prolactin — a hormone that can be elevated by certain antipsychotics (especially risperidone and paliperidone). Elevated prolactin can cause menstrual changes, breast tenderness or discharge, sexual dysfunction, and over the long term, bone density loss. Treatable by adjusting the medication.

• Treatment-resistant schizophrenia (TRS) — schizophrenia that has not responded adequately to at least two different antipsychotic medications tried at adequate doses for adequate durations. Defined this way because clozapine — the treatment of choice for TRS — is recommended after two prior failures. Affects roughly 20–30% of people with schizophrenia.
• Cognitive remediation — a structured, therapist-guided intervention using repeated exercises (often computer-based) to improve attention, memory, and problem-solving. Works best when combined with other rehabilitation such as supported employment. Not the same as “brain training” apps.
• Supported employment — helping people find and keep competitive, paid jobs in the community while receiving ongoing support from an employment specialist. Differs from sheltered workshops or pre-vocational training.
• IPS (Individual Placement and Support) — the specific model of supported employment with the strongest evidence base in schizophrenia. Key principles: rapid job search (no “get ready first” phase), competitive employment, integration with the mental health team, attention to worker preferences, and ongoing support after placement.

• Huntsman Mental Health Institute (HMHI) — University of Utah. Comprehensive psychiatric services including a first-episode psychosis program, inpatient and outpatient care, clozapine clinic, and clinical research/trials. 501 Chipeta Way, Salt Lake City. 801-583-2500.
• University of Utah Psychosis Research & Treatment Program — Early psychosis identification and intervention, coordinated specialty care, and research studies for schizophrenia spectrum disorders.

• McLean Hospital — Belmont, MA (Harvard Medical School affiliate). Schizophrenia and psychosis programs including the Psychotic Disorders Division, residential treatment, and clinical trials. 617-855-2000.
• Zucker Hillside Hospital — Glen Oaks, NY (Northwell Health / Feinstein Institutes). Recognition and Prevention (RAP) Program for early psychosis and the RAISE Connection Program. A leading center for first-episode psychosis research. 718-470-8000.
• Maryland Psychiatric Research Center (MPRC) — University of Maryland School of Medicine, Baltimore. Schizophrenia-focused research and treatment programs including the Treatment Research Program, clozapine optimization, cognitive remediation, and negative-symptom trials.

• VA Salt Lake City Health Care System — Mental Health — Outpatient psychiatry, psychosis treatment, psychosocial rehabilitation and recovery services, and peer support. 500 Foothill Drive, Salt Lake City. 801-582-1565.
• VA facilities offer clozapine clinics, long-acting injectable programs, and evidence-based psychosocial interventions (CBTp, supported employment) for veterans with schizophrenia.
• Veterans Crisis Line: Call 988, press 1. Text 838255. Chat at VeteransCrisisLine.net. Available 24/7.

• Centre for Addiction and Mental Health (CAMH) — Toronto. Canada’s largest mental health teaching hospital. Schizophrenia Division includes early-intervention services, clozapine clinic, brain stimulation research, and clinical trials. 416-535-8501.
• Douglas Mental Health University Institute — Montreal (McGill University affiliate). Prevention and Early Intervention Program for Psychosis (PEPP-Montreal), schizophrenia research, and specialized treatment programs. 514-761-6131.

• Maudsley Hospital / South London and Maudsley NHS Foundation Trust — London, UK (King’s College London). National Psychosis Unit, clozapine services, early-intervention programs, and the Maudsley Biomedical Research Centre for psychosis research. One of the world’s leading schizophrenia treatment and research centers.
• TIPS (Early Treatment and Intervention in Psychosis) — Stavanger, Norway. Pioneering early-intervention program whose research demonstrated that reducing the duration of untreated psychosis improves long-term outcomes. The TIPS model has influenced early-psychosis programs worldwide.

Amisulpride is a substituted-benzamide second-generation antipsychotic used across Europe, Australia, India, and more than 50 countries worldwide. It has a distinct pharmacological profile: at standard doses (400–800 mg/day) it blocks dopamine D2/D3 receptors and treats positive symptoms, while at low doses (50–300 mg/day) it preferentially blocks presynaptic autoreceptors, which may improve negative symptoms and dysthymia. This low-dose effect on negative symptoms is supported by clinical evidence and distinguishes amisulpride from most other antipsychotics.

Not FDA-approved for schizophrenia in the US. The only US-approved amisulpride product is intravenous amisulpride (Barhemsys), which is indicated solely for post-operative nausea and vomiting — an entirely different use. Oral amisulpride for psychiatric indications is unavailable in the United States. If you are transferring care from a country where oral amisulpride is prescribed, your US treatment team will need to transition you to an available alternative.

Side-effect profile. Amisulpride tends to cause less weight gain and sedation than olanzapine or quetiapine, but it can elevate prolactin levels significantly (sometimes more than risperidone) and carries a dose-dependent risk of QTc prolongation. Metabolic monitoring and ECG checks at higher doses are part of standard care in countries where it is prescribed.

Blonanserin is an atypical antipsychotic approved in Japan (PMDA, 2008), South Korea, India, and China. It acts primarily as a dopamine D2 and serotonin 5-HT2A antagonist with relatively low affinity for histamine and muscarinic receptors, which translates to less sedation and weight gain compared with some other second-generation antipsychotics. It is available in oral and transdermal patch formulations in Japan. Blonanserin is not available in the United States or Europe.

Perospirone is another atypical antipsychotic approved only in Japan. It combines D2 antagonism with 5-HT2A antagonism and 5-HT1A partial agonism. Its clinical profile is considered relatively mild in terms of metabolic effects, though it is less widely studied than other second-generation agents internationally. Like blonanserin, perospirone is not available outside Japan.

If you are relocating from Japan, South Korea, India, or China and are taking either of these medications, your new treatment team will need to identify the closest available alternative and manage the transition carefully.

While the section above describes the US and European monitoring landscape, it is important to note that Japan has the most restrictive clozapine monitoring system in the world. Japanese regulations require that clozapine be initiated only during an inpatient hospitalization, with mandatory weekly blood-count monitoring (white blood cell count and ANC) continuing throughout the entire course of treatment — there is no reduction to biweekly or monthly testing regardless of how long a patient has been stable.

This is substantially more restrictive than current US practice (where the REMS was eliminated in February 2025, leaving monitoring to prescriber judgment) and more restrictive than UK/European practice (which allows reduced monitoring frequency after the first year). The Japanese system, known as the Clozaril Patient Monitoring Service (CPMS), has contributed to very low clozapine utilization rates in Japan despite evidence that treatment-resistant schizophrenia affects patients at similar rates worldwide.

If you are moving between countries while on clozapine, be aware that the transition can involve significant changes in monitoring requirements, and planning ahead with both your current and future treatment teams is essential.